| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74ccc03b9160595016ddb907ed7ec5d3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 |
| filingDate |
2020-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adb5622bf63109c08e21e76e8e3ceb4a |
| publicationDate |
2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111588724-A |
| titleOfInvention |
Use of a composition containing a pyrrolopyrimidine derivative in the manufacture of a medicament for the treatment of Janus kinase-mediated diseases |
| abstract |
The purpose of the present invention is to provide the use of a composition containing a pyrrolopyrimidine derivative in the preparation of a medicament for the treatment of Janus kinase (JAK) mediated diseases, and the definition of the specific derivative is described in the specification. The inhibitory activity of the composition on various JAKs was significantly better than that of compound I. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112094274-A |
| priorityDate |
2020-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |